Interpreting 3-Year Data on Bimekizumab from BE RADIANT, With Ron Vender, MD

In the phase 3b BE RADIANT trial comparing bimekizumab with secukinumab in moderate to severe plaque psoriasis, investigators assessed not only traditional efficacy endpoints but also patient-reported outcomes (PROs) over 3 years. In discussing the results with HCPLive, Ronald Vender, MD, suggests PROs are among the most meaningful measures for the assessment of chronic inflammatory diseases.

In Vender’s interview, one of the most striking observations was the rapid onset of symptom relief with bimekizumab. After only 1 dose, by Week 4, subjects reported absence of pruritus, skin pain, and scaling at higher rates than those treated with secukinumab therapy. In parallel, some subjects attained complete skin clearance (PASI 0) and a Dermatology Life Quality Index (DLQI) score of 0 or 1, suggesting a minimal impact of disease on quality of life. For Vender, that early combination of objective clearance and subjective symptom resolution points to the clinical importance of rapid psoriasis control.

At 1 year, symptom resolution remained more frequent with bimekizumab, and Vender highlighted that the durability of response through year 3 is particularly reassuring. He noted clinicians often worry about waning biologic efficacy over the course of time. However, sustained lack of itch, pain, and scaling, coupled with maintained low DLQI scores and continued PASI 0 responses, suggests durable benefit. Importantly, he cautioned that clear skin does not always automatically translate to a low DLQI, making the concurrent achievement of both endpoints clinically meaningful.

When asked about long-term interpretation, Vender described the 3-year efficacy data as providing confidence in continued skin clearance and sustained quality-of-life improvements. He framed these results as supportive of ongoing utilization in appropriate patients, allowing clinicians to reassure those for whom the benefits can persist.

Finally, regarding a question on treatment sequencing, Vender described patients who shifted from secukinumab to bimekizumab as having experienced further improvements in symptom control and clearance. While acknowledging secukinumab remains an effective medication, he suggested the switching data suggest additional gains in PROs may be attainable with dual IL-17A/F inhibition in select individuals.

The quotes included in this summary were edited for clarity.

Vender reported support from AbbVie, Alumis, Amgen, Arcutis, Bausch, Bristol Myers Squibb, Celltrion, JAMP, Janssen, Leo, Lilly, Meiji, Novartis, Organon, Orka, Sandoz, Sun, Takeda, and UCB.

References

1. Augustin M, Feldman SR, Warren RB, et al. Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension. JAMA Dermatol. Published online February 18, 2026. doi:10.1001/jamadermatol.2025.6055.

2. Smith T. BE RADIANT Trial: Bimekizumab Effective for Psoriasis After 3 Years of Use. HCPLive. February 19, 2026. Accessed February 20, 2026. https://www.hcplive.com/view/be-radiant-trial-bimekizumab-effective-psoriasis-after-3-years-use.